199 related articles for article (PubMed ID: 28249258)
1. Apical Sodium-Dependent Transporter Inhibitors in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.
Hegade VS; Jones DE; Hirschfield GM
Dig Dis; 2017; 35(3):267-274. PubMed ID: 28249258
[TBL] [Abstract][Full Text] [Related]
2. Loss of apical sodium bile acid transporter alters bile acid circulation and reduces biliary damage in cholangitis.
Meadows V; Marakovits C; Ekser B; Kundu D; Zhou T; Kyritsi K; Pham L; Chen L; Kennedy L; Ceci L; Wu N; Carpino G; Zhang W; Isidan A; Meyer A; Owen T; Gaudio E; Onori P; Alpini G; Francis H
Am J Physiol Gastrointest Liver Physiol; 2023 Jan; 324(1):G60-G77. PubMed ID: 36410025
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis.
Baghdasaryan A; Fuchs CD; Österreicher CH; Lemberger UJ; Halilbasic E; Påhlman I; Graffner H; Krones E; Fickert P; Wahlström A; Ståhlman M; Paumgartner G; Marschall HU; Trauner M
J Hepatol; 2016 Mar; 64(3):674-81. PubMed ID: 26529078
[TBL] [Abstract][Full Text] [Related]
4. Hepatic NFAT signaling regulates the expression of inflammatory cytokines in cholestasis.
Cai SY; Yu D; Soroka CJ; Wang J; Boyer JL
J Hepatol; 2021 Mar; 74(3):550-559. PubMed ID: 33039404
[TBL] [Abstract][Full Text] [Related]
5. Biliary tract inflammatory disorders: primary sclerosing cholangitis and primary biliary cirrhosis.
Franco J; Saeian K
Curr Gastroenterol Rep; 1999 Apr; 1(2):95-101. PubMed ID: 10980934
[TBL] [Abstract][Full Text] [Related]
6. Phenotyping and auto-antibody production by liver-infiltrating B cells in primary sclerosing cholangitis and primary biliary cholangitis.
Chung BK; Guevel BT; Reynolds GM; Gupta Udatha DB; Henriksen EK; Stamataki Z; Hirschfield GM; Karlsen TH; Liaskou E
J Autoimmun; 2017 Feb; 77():45-54. PubMed ID: 27784538
[TBL] [Abstract][Full Text] [Related]
7. BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial.
Hegade VS; Kendrick SF; Dobbins RL; Miller SR; Richards D; Storey J; Dukes G; Gilchrist K; Vallow S; Alexander GJ; Corrigan M; Hirschfield GM; Jones DE
BMC Gastroenterol; 2016 Jul; 16(1):71. PubMed ID: 27431238
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice.
Miethke AG; Zhang W; Simmons J; Taylor AE; Shi T; Shanmukhappa SK; Karns R; White S; Jegga AG; Lages CS; Nkinin S; Keller BT; Setchell KD
Hepatology; 2016 Feb; 63(2):512-23. PubMed ID: 26172874
[TBL] [Abstract][Full Text] [Related]
9. Novel Aspects in the Management of Cholestatic Liver Diseases.
Chazouillères O
Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
[TBL] [Abstract][Full Text] [Related]
10. Alterations in tight junctions differ between primary biliary cirrhosis and primary sclerosing cholangitis.
Sakisaka S; Kawaguchi T; Taniguchi E; Hanada S; Sasatomi K; Koga H; Harada M; Kimura R; Sata M; Sawada N; Mori M; Todo S; Kurohiji T
Hepatology; 2001 Jun; 33(6):1460-8. PubMed ID: 11391535
[TBL] [Abstract][Full Text] [Related]
11. Chronic cholestatic liver diseases - Primary biliary cholangitis and Primary sclerosing cholangitis.
Fejfar T; Vaňásek T; Hůlek P
Vnitr Lek; 2020; 66(5):287-300. PubMed ID: 32942866
[TBL] [Abstract][Full Text] [Related]
12. Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis.
Sarcognato S; Sacchi D; Grillo F; Cazzagon N; Fabris L; Cadamuro M; Cataldo I; Covelli C; Mangia A; Guido M
Pathologica; 2021 Jun; 113(3):170-184. PubMed ID: 34294935
[TBL] [Abstract][Full Text] [Related]
13. [Novel Insights of Primary Sclerosing Cholangitis and Primary Biliary Cholangitis].
Ahn DW
Korean J Gastroenterol; 2020 May; 75(5):246-256. PubMed ID: 32448856
[TBL] [Abstract][Full Text] [Related]
14. Impact of Microbes on the Pathogenesis of Primary Biliary Cirrhosis (PBC) and Primary Sclerosing Cholangitis (PSC).
Mattner J
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834858
[TBL] [Abstract][Full Text] [Related]
15. Impaired Hepatic Adaptation to Chronic Cholestasis induced by Primary Sclerosing Cholangitis.
Milkiewicz M; Klak M; Kempinska-Podhorodecka A; Wiechowska-Kozlowska A; Urasinska E; Blatkiewicz M; Wunsch E; Elias E; Milkiewicz P
Sci Rep; 2016 Dec; 6():39573. PubMed ID: 28008998
[TBL] [Abstract][Full Text] [Related]
16. Cholestatic Pruritus Treatments in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: A Systematic Literature Review.
Smith HT; de Souza AR; Thompson AH; McLaughlin MM; Dever JJ; Myers JA; Chen JV
Dig Dis Sci; 2023 Jun; 68(6):2710-2730. PubMed ID: 36933112
[TBL] [Abstract][Full Text] [Related]
17. Adhesion molecule expression in primary sclerosing cholangitis and primary biliary cirrhosis.
Bloom S; Fleming K; Chapman R
Gut; 1995 Apr; 36(4):604-9. PubMed ID: 7537707
[TBL] [Abstract][Full Text] [Related]
18. Primary biliary cirrhosis and primary sclerosing cholangitis.
Angulo P; Lindor KD
Clin Liver Dis; 1999 Aug; 3(3):529-70. PubMed ID: 11291238
[TBL] [Abstract][Full Text] [Related]
19. Primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune cholangitis.
Sherlock S
Clin Liver Dis; 2000 Feb; 4(1):97-113. PubMed ID: 11232193
[TBL] [Abstract][Full Text] [Related]
20. Complications, symptoms, quality of life and pregnancy in cholestatic liver disease.
Zakharia K; Tabibian A; Lindor KD; Tabibian JH
Liver Int; 2018 Mar; 38(3):399-411. PubMed ID: 28921801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
